Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04929353 | SYSTEMATIC SYMPTOM ASSESSMENT IN CANCER PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS(IRMA) | unknown | N/A | 280 | University Of PerugiaOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT04928365 | Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy | unknown | Phase 2 | 50 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Jun 16, 2021 | clinicaltrials |
| NCT04628806 | Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells(HSP70CTC) | unknown | — | 120 | Charite University, Berlin, GermanyOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT04884997 | A Study of Toripalimab or Combining With Temozolomide（iv） in the Treatment of Advanced/Metastatic Malignant Melanoma | unknown | Phase 2 | 90 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT03754179 | Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma(COMBI-R2) | unknown | Phase 1 / Phase 2 | 63 | Universitair Ziekenhuis BrusselOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02913417 | Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases | unknown | Phase 1 / Phase 2 | 26 | David Minor, MDOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT03313323 | Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma(Zirconipi) | unknown | Phase 2 | 29 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT02501551 | Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy | unknown | Phase 2 | 36 | Yonsei UniversityOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT01676649 | Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma | unknown | Phase 2 | 30 | Jewish General HospitalOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT02617849 | Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma | unknown | Phase 2 | 30 | Wilson MillerOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT04756934 | A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma | unknown | Phase 1 | 63 | Taizhou HoudeAoke Biomedical Co., Ltd.INDUSTRY | 1 | Feb 16, 2021 | clinicaltrials |
| NCT04749485 | A Study of HX008 for the Treatment of Patients With Malignant Melanoma | unknown | Phase 2 | 119 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 11, 2021 | clinicaltrials |
| NCT04197882 | Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma | unknown | Phase 1 | 33 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT04625491 | Location of Lower Limb Cutaneous Melanomas as a Prognostic Factor. | unknown | — | 300 | Hospital Universitario Virgen de la ArrixacaOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT01503827 | Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma(WBRTMel) | unknown | N/A | 220 | Melanoma and Skin Cancer Trials LimitedOTHER | 3 | Jan 7, 2021 | clinicaltrials |
| NCT04695015 | Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm | unknown | — | 100 | Peking UniversityOTHER | 0 | Jan 5, 2021 | clinicaltrials |
| NCT03747744 | Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC)(myDCTV) | unknown | Phase 1 | 18 | Universitair Ziekenhuis BrusselOTHER | 1 | Dec 29, 2020 | clinicaltrials |
| NCT04593485 | Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract | unknown | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT02673970 | Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma(ICIT) | unknown | — | 200 | Universitair Ziekenhuis BrusselOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT02907827 | Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.(DW-MRi) | unknown | N/A | 100 | Universitair Ziekenhuis BrusselOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03088176 | Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma | unknown | Phase 1 | 4 | West Cancer CenterOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT04583605 | The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin Tumors | unknown | — | 90 | Central Hospital, Nancy, FranceOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT03013101 | Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma | unknown | Phase 2 | 128 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT03086174 | Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma | unknown | Phase 1 | 24 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT03269565 | International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma(MIRACULUM) | unknown | Phase 2 | 126 | BiocadINDUSTRY | 1 | Sep 18, 2020 | clinicaltrials |
| NCT04021420 | Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma(SONIMEL01) | unknown | Phase 1 / Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT04136470 | BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics | unknown | — | 130 | ArdigenINDUSTRY | 1 | Aug 10, 2020 | clinicaltrials |
| NCT04472806 | Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma(MTAM) | unknown | Phase 2 | 31 | Fudan UniversityOTHER | 1 | Jul 15, 2020 | clinicaltrials |
| NCT04397770 | Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma | unknown | Phase 2 | 40 | Peking University Cancer Hospital & InstituteOTHER | 0 | May 21, 2020 | clinicaltrials |
| NCT04072900 | A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma | unknown | Phase 1 | 30 | Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT04357509 | The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma | unknown | Phase 1 | 32 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT03643289 | Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics(PRIMM) | unknown | — | 450 | East and North Hertfordshire NHS TrustOTHER_GOV | 1 | Feb 27, 2020 | clinicaltrials |
| NCT04200040 | A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients | unknown | Phase 2 | 165 | OrienGene Biotechnology Ltd.INDUSTRY | 1 | Feb 27, 2020 | clinicaltrials |
| NCT04261179 | Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer(SENTINELSEEK) | unknown | Phase 4 | 30 | Anna CrucetaOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT04268368 | Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors(ICI-DISCOVER) | unknown | — | 200 | Università Politecnica delle MarcheOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT04250246 | A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1(NIBIT-ML1) | unknown | Phase 2 | 184 | Italian Network for Tumor Biotherapy FoundationOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT04234620 | Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) . | unknown | — | 800 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT04206358 | Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma | unknown | Phase 1 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT03649529 | Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy | unknown | Early Phase 1 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Dec 6, 2019 | clinicaltrials |
| NCT03941795 | Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma(BJCH-MM-0624) | unknown | Phase 2 | 99 | Peking University Cancer Hospital & InstituteOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT04169867 | Polish Microbiome Map | unknown | — | 1,160 | ArdigenINDUSTRY | 1 | Nov 20, 2019 | clinicaltrials |
| NCT04001725 | Efficacy of metfOrmin in PrevenTIng Glucocorticoid-induced Diabetes in Patients With Brain Metastases(OPTIMAL) | unknown | Phase 2 | 110 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT04158544 | Immune Monitoring in Metastatic Melanoma | unknown | — | 100 | University of RegensburgOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01088737 | Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna | unknown | Phase 2 / Phase 3 | 60 | Medical University of GrazOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT04017897 | The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma | unknown | Phase 2 | 52 | Yonsei UniversityOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT03602547 | Study of the Combination of CM082 With JS001 in Patients With Advanced Mucosal Melanoma. | unknown | Phase 2 | 40 | AnewPharmaINDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jun 18, 2021source: clinicaltrials